If the loophole is not closed, more sponsors could follow the pathway that allowed remdesivir to receive an orphan drug designation as a coronavirus treatment, the writers of a JAMA Internal Medicine article argued. • Source: Shutterstock
Learn what's happening at the US FDA. On the go.
Derrick Gingery and the team bring you a weekly "Drug Fix".
